Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November ...
Semler Scientific, Inc. (Nasdaq: SMLR) today announced the pricing of its offering of $85.0 million aggregate principal amount of 4.25% convertible senior notes due 2030 (the "notes") in a private ...